SlideServe
Télécharger Obtenir Pro
Menu
Accueil Pro
Préférences
ApparenceLight Aide et commentaires
© SlideServe · v2026

Monitoring Entry, Retention, and ART Adherence: Key Strategies for HIV Care Management

prentice avatar
prentice
19 diapositives · 344 Views · Jul 26, 2014

This presentation by Dr. Robert Gross focuses on the critical monitoring of entry, retention, and adherence in HIV treatment. Emphasizing the importance of timely entry into care for improved survival, it outlines challenges in logistics and data collection. The presentation further highlights various metrics for retention, the necessity of integration of data sources, and personalized adherence monitoring strategies. Essential tools such as self-reports and pharmacy refill data are examined, offering insights into effective care interventions. Continued monitoring can preempt treatment failures and enhance patient outcomes.

#monitoring entry, retention, and art adherence: key strategies for hiv care management #monitoring entry, retention, and art adherence: key strategies for hiv care management ppt #powerpoint #presentation
Monitoring Entry, Retention, and ART Adherence: Key Strategies for HIV Care Management - slide 1
01 / 19Monitoring Entry, Retention, and ART Adherence: Key Strategies for HIV Care Management
1 / 17

Télécharger la présentation

Monitoring Entry, Retention, and ART Adherence: Key Strategies for HIV Care Management
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation

  1. Penn Infectious Diseases CCEB Monitoring Entry, Retention, and ART Adherence Robert Gross, MD MSCE Associate Professor of Medicine (ID) and Epidemiology University of Pennsylvania Perelman School of Medicine

  2. Monitoring Overview • Most research on adherence • Entry and retention have emerged as highly important • Less data available on “how to” • More local logistics come into play • Overarching message • “Monitoring provides key data on which patients need interventions”

  3. Entry Monitoring • Entry into care shortly after dx associated with survival • Monitoring challenge • Multiple sources of data (e.g., dedicated testing sites, clinics) • Responsible parties need to be identified and logistics arranged

  4. Retention Monitoring • Retention has multiple benefits • Decreased morbidity/mortality • Decreased community viral load • Various metrics used • Visit adherence, gaps in care, visits per time frame • Logistics easier than for entry • Use medical records and admin data • May require integration of sources

  5. Adherence Vignette • 45 y.o. HIV infected man • Philadelphia VAMC • Serial monoRx in 90s, then HAART • Excellent adherence, but multiple resistance mutations acquired • CD4=0 (0%) x 3 years • New regimen • DRV/r in combination therapy • HIV-1 RNA <50 c/ml, CD4~300 cells/mm3

  6. Why Monitor? • Follow-up visit • HIV-1 RNA<50 copies/ml • Queried re: adherence as always • Had stopped meds entirely for 3 wks! • New onset depression • Depression/non-adherence overcome • Resumed adherence and no subsequent virologic failure

  7. Need for Continued Monitoring • Can detect impending failure • Irrespective of viral load monitoring (e.g., Bisson G, Gross R et al. PLoS Med 2008) • Intervention before failure • Same principles likely for entry and retention in care

  8. False Security of RNA Suppression • ATH02 study • Observational • EFV-based regimen • HIV-1 RNA<75 copies/ml • Monitored RNA monthly • MEMS for adherence monitoring • Follow until breakthrough or 1 year Gross R et al, HIV Clinical Trials, 2008

  9. Timing of Adherence and Outcome Adherence interval without time shift time event or censor date Adherence interval with time shift time shift

  10. Timing of Non-Adherence

  11. Monitoring Recommendations • Assess adherence each visit • Self-report • Pharmacy refill data (MPR) • Do not recommend microelectronic monitors at this time • Do not recommend drug concentrations at this time • Do not recommend routine pill counts

  12. Self-Reports • Must use non-judgmental tone • Preamble admitting perfect adherence unrealistic, but desired • Allow for honesty • Specify time period of recall • Multiple potential tools • Choice of tool site specific

  13. Self-Report Examples • ACTG questionnaire • How many doses missed yesterday, 1, 2, and 3 days before • How many doses missed over w/e? • When last dose missed? • Visual Analog Scale • Ask ~how many doses taken over past month • Place X on graduated line

  14. Use of Pharmacy Refill Data • Specify period of interest • Past 1, 2, 3 months for example • Cannot be shorter than length of days supply • Too long may be irrelevant data • Ensure full data capture • If centralized pharmacy: simple • If multiple commercial pharmacies: logistically challenging, but feasible

  15. Medication Possession Ratio Time First fill Second fill Third fill Fourth fill } } } First interval Second interval Third interval Adherence metric: (Σ interval days supply)/(4th fill date-1st fill date) Grossberg R et al, J Clin Epi 2004

  16. Drug Concentrations • Variable association with outcome • Some drugs strongly associated • Different pts on different drugs • Variability across drugs limits programmatic utility • Logistical limitations • Need for specimens (blood, hair) • Need for sophisticated lab • Turnaround time • Cost

  17. Pill Counts • Weak association with outcome • Yet commonly used • Demanding of staff time • Other value • Limits dispensing expensive drug if supply not used • Can add information to pharmacy refill data

  18. Microelectronic monitors • Strongly associated with outcome • Can provide objective feedback • Useful in intervention • Granular view of dose timing and daily taking • Logistical limitations • Cumbersome • Inconvenient (cannot pocket doses) • Cost

  19. Conclusions • Monitor entry in care • Collate sources of data • Establish responsibilities for linkage • Monitor retention • Track clinic administrative records • Monitor adherence • Self-report or refill records • Other techniques need refinement or replacement